Bradley Sandler, MD
Ophthalmology · Fairfield, CANPI 1932102415
Payments from drug & device makers
Across 114 payments — averaging $45.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Apellis Pharmaceuticals, Inc.$450
- Genentech USA, Inc.$395
- Biotissue Holdings Inc.$364
- AbbVie$347
- Aerie Pharmaceuticals, Inc.$313
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,14099%
- Gifts$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 37 | $1,741 |
| Apellis Pharmaceuticals, Inc. | 4 | $450 |
| Genentech USA, Inc. | 3 | $395 |
| Biotissue Holdings Inc. | 5 | $364 |
| AbbVie(2 entities) | 9 | $347 |
| Aerie Pharmaceuticals, Inc. | 6 | $313 |
| Amgen(2 entities) | 8 | $269 |
| Tarsus Pharmaceuticals, Inc. | 8 | $184 |
| Rxsight Inc | 3 | $166 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $155 |
| Sun Pharmaceutical Industries Inc. | 6 | $132 |
| Genentech, Inc. | 1 | $122 |
| Ellexiscience | 1 | $105 |
| Thea Pharma Inc. | 3 | $62 |
| Mallinckrodt Hospital Products Inc. | 3 | $53 |
| Harrow Eye, LLC | 2 | $44 |
| Merz Pharmaceuticals, LLC | 1 | $44 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $42 |
| Oyster Point Pharma, Inc. | 2 | $36 |
| Glaukos Corporation | 1 | $32 |
| NEW World Medical,inc. | 1 | $28 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
| Novartis | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Dompe US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$517
- Clareon$359
- Rhopressa$344
- Rocklatan$344
- Syfovre$330
- XDEMVY$127
- TEPEZZA$125
- TRYPTYR$123
- ENVISTA$121
- RXSIGHT CONTACT LENS$119
- RXSIGHT INJECTOR CARTRIDGE$119
- RXSIGHT INJECTOR HANDPIECE$119
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$119
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$119
- DURYSTA$114
- AcrySof IQ PanOptix$113
- Hydrus Microstent$102
- Luxor$100
How this compares
$5,177 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 25 | $34,761 |
| LumiganBimatoprost | 49 | $29,298 |
| RocklatanNetarsudil Mesylat/Latanoprost | 37 | $25,153 |
| Cyclosporine | 66 | $23,949 |
| XiidraLifitegrast | 11 | $18,197 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 49 | $11,365 |
| Latanoprost | 582 | $7,320 |
| IlevroNepafenac | 13 | $4,834 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $3,914 |
| Brinzolamide | 22 | $3,358 |
| Prednisolone Acetate | 82 | $3,318 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 194 | $3,196 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 16 | $2,739 |
| Diclofenac Sodium | 236 | $2,375 |
| Timolol Maleate | 170 | $1,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $347 | $64,05874 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $313 | $25,15337 claims |
| Bausch & Lomb Americas Inc.Xiidra | $23 | $18,19711 claims |
| AlconSimbrinza | $1,741 | $11,36549 claims |
| NovartisIlevro | $21 | $4,83413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Fairfield
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.